Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 4.
doi: 10.1111/cei.13450. Online ahead of print.

Using IL-2R/lymphocytes for Predicting the Clinical Progression of Patients With COVID-19

Affiliations

Using IL-2R/lymphocytes for Predicting the Clinical Progression of Patients With COVID-19

H Hou et al. Clin Exp Immunol. .

Abstract

Effective laboratory markers for the estimation of disease severity and predicting the clinical progression of coronavirus disease-2019 (COVID-19) is urgently needed. Laboratory tests, including blood routine, cytokine profiles and infection markers, were collected from 389 confirmed COVID-19 patients. The included patients were classified into mild (n = 168), severe (n = 169) and critical groups (n = 52). The leukocytes, neutrophils, infection biomarkers [such as C-reactive protein (CRP), procalcitonin (PCT) and ferritin] and the concentrations of cytokines [interleukin (IL)-2R, IL-6, IL-8, IL-10 and tumor necrosis factor (TNF)-α] were significantly increased, while lymphocytes were significantly decreased with increased severity of illness. The amount of IL-2R was positively correlated with the other cytokines and negatively correlated with lymphocyte number. The ratio of IL-2R to lymphocytes was found to be remarkably increased in severe and critical patients. IL-2R/lymphocytes were superior compared with other markers for the identification of COVID-19 with critical illness, not only from mild but also from severe illness. Moreover, the cytokine profiles and IL-2R/lymphocytes were significantly decreased in recovered patients, but further increased in disease-deteriorated patients, which might be correlated with the outcome of COVID-19. Lymphopenia and increased levels of cytokines were closely associated with disease severity. The IL-2R/lymphocyte was a prominent biomarker for early identification of severe COVID-19 and predicting the clinical progression of the disease.

Keywords: COVID-19; IL-2R/lymphocyte ratio; SARS-CoV-2; clinical progression; cytokine.

Similar articles

See all similar articles

References

    1. Zhu N, Zhang D, Wang Wet al., China Novel Coronavirus I, Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727-33.
    1. Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm. Eur J Clin Invest 2020; 50:e13209.
    1. Rothe C, Schunk M, Sothmann P et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020; 382:970-1.
    1. The L. Emerging understandings of 2019-nCoV. Lancet 2020; 395:311.
    1. Wu Z, McGoogan JM. Characteristics of and Important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323:1239-42.

LinkOut - more resources

Feedback